Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
T-Lymphocytes
immunomodulation
lymphocytes
tumor microenvironment
tumor-Infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
29
09
2020
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
Treatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor's immune-suppressive stromal compartment. New evidence of positive effects on immune responses in the tumor microenvironment (TME), compelled us to test the combination of gemcitabine (GEM), a standard chemotherapeutic for pancreatic cancer, with nicotinamide (NAM), the amide form of niacin (vitamin B Various mouse tumor models of pancreatic cancer, that is, orthotopic Panc-02 and KPC (Kras A significant reduction in tumor weight and number of metastases was found, as well as a significant improved survival of the NAM+GEM group compared with all control groups. IHC and flow cytometry showed a significant decrease in tumor-associated macrophages and myeloid-derived suppressor cells in the tumors of NAM+GEM-treated mice. This correlated with a significant increase in the number of CD4 and CD8 T cells of NAM+GEM-treated tumors, and CD4 and CD8 T cell responses to tumor-associated antigen survivin, most likely through epitope spreading. In vivo depletions of T cells demonstrated the involvement of CD4 T cells in the eradication of the tumor by NAM+GEM treatment. In addition, remodeling of the tumor stroma was observed with decreased collagen I and lower expression of hyaluronic acid binding protein, reorganization of the immune cells into lymph node like structures and CD31 positive vessels. Expression profiling for a panel of immuno-oncology genes revealed significant changes in genes involved in migration and activation of T cells, attraction of dendritic cells and epitope spreading. This study highlights the potential of NAM+GEM as immunotherapy for advanced pancreatic cancer.
Sections du résumé
BACKGROUND
Treatments for pancreatic ductal adenocarcinoma are poorly effective, at least partly due to the tumor's immune-suppressive stromal compartment. New evidence of positive effects on immune responses in the tumor microenvironment (TME), compelled us to test the combination of gemcitabine (GEM), a standard chemotherapeutic for pancreatic cancer, with nicotinamide (NAM), the amide form of niacin (vitamin B
METHODS
Various mouse tumor models of pancreatic cancer, that is, orthotopic Panc-02 and KPC (Kras
RESULTS
A significant reduction in tumor weight and number of metastases was found, as well as a significant improved survival of the NAM+GEM group compared with all control groups. IHC and flow cytometry showed a significant decrease in tumor-associated macrophages and myeloid-derived suppressor cells in the tumors of NAM+GEM-treated mice. This correlated with a significant increase in the number of CD4 and CD8 T cells of NAM+GEM-treated tumors, and CD4 and CD8 T cell responses to tumor-associated antigen survivin, most likely through epitope spreading. In vivo depletions of T cells demonstrated the involvement of CD4 T cells in the eradication of the tumor by NAM+GEM treatment. In addition, remodeling of the tumor stroma was observed with decreased collagen I and lower expression of hyaluronic acid binding protein, reorganization of the immune cells into lymph node like structures and CD31 positive vessels. Expression profiling for a panel of immuno-oncology genes revealed significant changes in genes involved in migration and activation of T cells, attraction of dendritic cells and epitope spreading.
CONCLUSION
This study highlights the potential of NAM+GEM as immunotherapy for advanced pancreatic cancer.
Identifiants
pubmed: 33154149
pii: jitc-2020-001250
doi: 10.1136/jitc-2020-001250
pmc: PMC7646363
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Deoxycytidine
0W860991D6
Vitamin B Complex
12001-76-2
Niacinamide
25X51I8RD4
Gemcitabine
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Photochem Photobiol Sci. 2020 Feb 19;19(2):171-179
pubmed: 31942903
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Nat Commun. 2020 Jul 30;11(1):3819
pubmed: 32732875
Trends Pharmacol Sci. 2003 May;24(5):228-32
pubmed: 12767721
J Immunol. 2002 Feb 1;168(3):1001-8
pubmed: 11801632
Pancreatology. 2013 Mar-Apr;13(2):140-6
pubmed: 23561972
Br J Cancer. 2014 Nov 11;111(10):1917-23
pubmed: 25314063
Annu Rev Pathol. 2008;3:157-88
pubmed: 18039136
Intravital. 2016 Nov 18;5(3):e1261773
pubmed: 28243522
J Immunol. 2007 Oct 15;179(8):5474-82
pubmed: 17911634
J Clin Oncol. 2007 Oct 20;25(30):4787-92
pubmed: 17947726
Oncotarget. 2016 Jan 26;7(4):4183-94
pubmed: 26716653
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
PLoS One. 2012;7(10):e46677
pubmed: 23056397
Sci Rep. 2017 Mar 09;7:43989
pubmed: 28276533
Br J Cancer. 2008 Sep 2;99(5):741-9
pubmed: 18728665
Gastroenterology. 2013 Nov;145(5):1121-32
pubmed: 23891972
N Engl J Med. 2015 Oct 22;373(17):1618-26
pubmed: 26488693
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
Aging Cell. 2015 Feb;14(1):67-77
pubmed: 25495009
Oncol Rep. 2015 Feb;33(2):721-8
pubmed: 25504347
Cancer Lett. 2016 Oct 10;381(1):217-36
pubmed: 26742462
Molecules. 2009 Sep 09;14(9):3446-85
pubmed: 19783937
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Cell Mol Med. 2009 Sep;13(9B):4023-33
pubmed: 20196789
J Immunol. 2003 Sep 15;171(6):2797-803
pubmed: 12960300
Cancer Immunol Res. 2017 Nov;5(11):978-991
pubmed: 29066497
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Cancer Res. 2003 Aug 1;63(15):4490-6
pubmed: 12907622
Cancer Lett. 2014 Feb 28;343(2):147-55
pubmed: 24141189
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
pubmed: 16166452
Cancer Immunol Immunother. 2005 Sep;54(9):915-25
pubmed: 15782312
Clin Cancer Res. 2019 Apr 1;25(7):2194-2205
pubmed: 30385653
Virology. 2014 Aug;462-463:175-88
pubmed: 24999042
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Oncoimmunology. 2017 Jul 5;6(9):e1342025
pubmed: 28932647
Oncogene. 2011 Mar 24;30(12):1449-59
pubmed: 21102519
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
J Immunol. 2015 Mar 15;194(6):2786-95
pubmed: 25667415
Curr Opin Gastroenterol. 2015 Sep;31(5):416-23
pubmed: 26125317
Onco Targets Ther. 2019 Feb 28;12:1691-1703
pubmed: 30881024
Front Immunol. 2014 Apr 15;5:174
pubmed: 24782871
Mol Cells. 2015 Oct;38(10):918-24
pubmed: 26442863
Mol Immunol. 2019 Oct;114:172-178
pubmed: 31357083
Cancer Immunol Immunother. 2011 Jan;60(1):99-109
pubmed: 20960189
Cancer Manag Res. 2019 Mar 27;11:2457-2470
pubmed: 30988641
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
Cells. 2019 May 13;8(5):
pubmed: 31086070
Oncoimmunology. 2013 Dec 1;2(12):e26836
pubmed: 24498556
Br J Cancer. 2009 Oct 20;101(8):1329-37
pubmed: 19826426
Cancer Res. 1984 Feb;44(2):717-26
pubmed: 6692374